Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 10953113
Imaging agents and methods of use
granted -
US 10954304
Neutralizing antibodies to the Ξ±vΞ²8 integrin complex for immunotherapy
granted -
US 10953028
Method of treating heterotopic ossification
granted -
US 10953209
Treating tumors using TTFields combined with a PARP inhibitor
granted -
US 10953040
Methods of treating bacterial infections with penam Ξ²-lactam antibiotics and branched poly(ethylenimine)
granted -
US 10947206
cGAS antagonist compounds
granted -
US 10947507
Platform for generating safe cell therapeutics
granted -
US 10945993
Methods of recruiting SDF-producing macrophages
granted -
US 10945962
Controlled-release peptide compositions and uses thereof
granted -
US 10945996
Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis
granted -
US 10946096
Nitrobenzaldehyde proton release for manipulation of cellular acidosis
granted -
US 10946106
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
granted -
US 10947207
GP130 modulators
granted -
US 10947302
Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them
granted -
US 10947238
Wee1 kinase inhibitors and methods of making and using the same
granted -
US 10947198
Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents
granted -
US 10940160
Biomarkers for predicting responsiveness to decitabine therapy
granted -
US 10940168
Method of treating Bruch's membrane hypofunction disease
granted -
US 10940109
Multilayer polymeric matrix based medical devices
granted -
US 10941175
Pyrrolopyrimidine nucleosides and analogs thereof
granted -
US 10941433
Neurotransmitter transport in probiotics
granted -
US 10942183
Methods of detecting progesterone receptor and of detecting an expression level
granted -
US 10940214
Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord
granted -
US 10941392
Purification of cystathionine beta-synthase
granted -
US 10933042
Intravenous baclofen formulations and treatment methods
granted -
US 10933071
Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof
granted -
US 10933078
Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
granted -
US 10934527
Generation of lineage-restricted progenitor cells from differentiated cells
granted -
US 10933126
Clostridium difficile immunogenic compositions and methods of use
granted -
US 10934334
Peptides for angiogenic therapy
granted -
US 10934264
Amyloid targeting agents and methods of using the same
granted -
US 10934332
Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment
granted -
US 10925977
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
granted -
US 10927160
Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof
granted -
US 10927135
Metal-free direct arylation of dialkyl phosphonates for the synthesis of mixed alkyl aryl phosphonates
granted -
US 10927349
Platform for generating safe cell therapeutics
granted -
US 10925923
Peptide having anti-inflammatory activity, and use thereof
granted -
US 10925928
Method for treating chemotherapy-induced male infertility
granted -
US 10927193
Gellan gum-based hydrogels, methods and uses thereof
granted -
US 10925972
Glycan-dependent immunotherapeutic molecules
granted -
US 10925975
Acidic nanoparticles for restoration of autophagy
granted -
US 10928391
CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease
granted -
US 10927165
Antibodies that neutralize botulinum neurotoxins
granted -
US 10925851
Use of Tosedostat and related compounds as analgesics
granted -
US 10919877
Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same
granted -
US 10918657
Treatment of spinal cord injury or traumatic brain injury by inhibition of synuclein protein aggregation
granted -
US 10918594
Controlled-release CNS modulating compositions and methods for the treatment of otic disorders
granted -
US 10918648
Estrogen receptor modulator combinations
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory